Supplementary Figures S1 - S5 from Heterogeneity Underlies the Emergence of &lt;i&gt;EGFR&lt;/i&gt;&lt;sup&gt;T790&lt;/sup&gt; Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor